Laryngoscope:鼻用糖皮质激素不能导致眼部变化

2018-10-08 AlexYang MedSci原创

鼻用糖皮质激素(INCS)的安全性和效果已经有了很好的评估,但是INCS仍具存在忧虑,即能够导致系统性的副作用,类似于口服类固醇。最近,有研究人员系统性的评估了是否INCS的使用能够增加眼内压(IOP)超过20mmHg、青光眼或者后囊下内障在鼻炎患者中的形成。研究总共包括了484个研究,其中有10个随机对照试验符合他们的标准。与安慰剂组对比,对2226名患者的元分析阐释了IOP提高的相对风险在那些

鼻用糖皮质激素(INCS)的安全性和效果已经有了很好的评估,但是INCS仍具存在忧虑,即能够导致系统性的副作用,类似于口服类固醇。最近,有研究人员系统性的评估了是否INCS的使用能够增加眼内压(IOP)超过20mmHg、青光眼或者后囊下内障在鼻炎患者中的形成。

研究总共包括了484个研究,其中有10个随机对照试验符合他们的标准。与安慰剂组对比,对2226名患者的元分析阐释了IOP提高的相对风险在那些接受INCS治疗的参与者中为2.24(95%置信区间(CI):0.68到7.34)。使用INCS的患者提高的IOP绝对增加率与对照组比较为0.8%(95% CI: 0% 到1.6%)。在12个月时,安慰剂组和INCS组的青光眼案例数为0。另外,发展为后囊下白内障的绝对增加率为0.02%(95% CI: -0.3%到0.4%)。

最后,研究人员指出,在过敏性鼻炎患者中,INCS的使用与IOP风险的显著增加或者发展为后囊下白内障风险的增加不相关。青光眼虽然存在于副作用事件中,但是他们的研究在12个月时并未见报道。

原始出处:

Valenzuela CV, Liu JC, Vila PM et al. Intranasal Corticosteroids Do Not Lead to Ocular Changes: A Systematic Review and Meta-analysis. Laryngoscope. 19 Sep 2018.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727673, encodeId=9f571e27673ef, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 16 02:54:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701237, encodeId=88b41e01237e8, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Dec 16 21:54:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776079, encodeId=6bd01e76079a4, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 28 09:54:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600360, encodeId=eb261600360d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Oct 10 03:54:00 CST 2018, time=2018-10-10, status=1, ipAttribution=)]
    2019-05-16 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727673, encodeId=9f571e27673ef, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 16 02:54:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701237, encodeId=88b41e01237e8, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Dec 16 21:54:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776079, encodeId=6bd01e76079a4, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 28 09:54:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600360, encodeId=eb261600360d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Oct 10 03:54:00 CST 2018, time=2018-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727673, encodeId=9f571e27673ef, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 16 02:54:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701237, encodeId=88b41e01237e8, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Dec 16 21:54:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776079, encodeId=6bd01e76079a4, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 28 09:54:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600360, encodeId=eb261600360d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Oct 10 03:54:00 CST 2018, time=2018-10-10, status=1, ipAttribution=)]
    2018-12-28 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727673, encodeId=9f571e27673ef, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 16 02:54:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701237, encodeId=88b41e01237e8, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Dec 16 21:54:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776079, encodeId=6bd01e76079a4, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Fri Dec 28 09:54:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600360, encodeId=eb261600360d0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Wed Oct 10 03:54:00 CST 2018, time=2018-10-10, status=1, ipAttribution=)]

相关威廉亚洲官网

盘点:鼻炎与治疗研究进展

【1】Curr Med Res Opin:一个大群体的舌下免疫治疗花费研究 在美国人口中,过敏性鼻炎(AR)影响的人数占比了高达40%,每年的医疗花费大约110亿美元。过敏免疫治疗是长期症状缓解的最好的选择,但是治疗依从性低。最近,有研究人员调查了那些接受全部免疫治疗和那些免疫治疗间断患者的舌下免疫治疗(SCIT)相关的花费情况。研究发现,与对照(n=394479)相比,SCIT(n

盘点:鼻部疾病研究进展

【1】Environ Pollut:大气中的粗细颗粒能够对鼻腔和支气管上皮细胞产生不同的影响和诱发不同的免疫响应大气中的颗粒物质(PM)在流行病学上能够加速恶化呼吸和免疫健康,包括过敏性鼻炎(AR)和支气管哮喘(BA)。尽管精细的和粗大的颗粒能够影响呼吸道,然而他们对上呼吸道和下呼吸道以及免疫系统的影响差异、它们潜在的机制和对健康造成不良影响的组成仍旧还没有完全的阐释。最近,有研究人员利用旋流

Expert Opin Pharmacother:苯磺酸贝托司汀在永久过敏性鼻炎中的治疗结果分析

苯磺酸贝托司汀(BB)是二代H1抗组胺药物,作为一种滴眼液,在美国是通过FDA批准的可以用于过敏性结膜炎治疗的药物。在其他的国家,口服BB是广泛存在的,主要是用于过敏性鼻炎(AR)以及荨麻疹和慢性瘙痒症状的改善,并且与其他药物治疗的结果类似。最近,有研究人员对文献进行了综合的搜索,这些文献的信息均来自临床试验。研究人员评估了BB的临床和非临床药理学情况,以及在AR中的使用和对症状的改善情况,还探究

Clin Exp Allergy:6岁时候的非特应性鼻炎与随后哮喘的发展相关

之前,有研究人员假设过敏性鼻炎与哮喘的相关性可以归结到儿童时期呼吸道炎症的持续临床表现。早期非过敏性鼻炎与哮喘的关系仍旧没有很好的研究。最近,有研究人员进行了旨在确定是否早期的鼻炎与成年时候的哮喘的风险相关,以及是否该相关性与过敏无关。研究总共有521名参与者符合入选要求。与非特应性非鼻炎组相比,在调整了性别、种族、母亲肖传、母亲教育和抽烟以及6岁时不少于4次感冒历史后,非特应性鼻炎患者在8岁到3

J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析

最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘之间的相关性。研究人员分析了2011年11210名主要农场经营者的农场和牧场安全调查数据。农药的使用通过调查问卷的方式来进行确定,即询问在调查前的12个月内是否混合、装载或者使用农药。那些回答肯定的参与者进一步询问商品的名称和产品的制定标识符以及个人的防护设备(PPE)情况。研究人员对数据进行了加权从而对全国的情况进行评估,

NPJ Prim Care Respir Med:过敏性鼻炎治疗中关键影响因素鉴定分析

过敏性鼻炎(AR)越来越成为一种患者自身治疗的疾病。不多于70%的患者自己选择购买药物进行治疗,且没有专业人员的干预,其治疗结果总是令人不满意,这也导致了鼻炎不良治疗,增加了AR治疗对个人和社会的负担。然而,没有外部的影响也就没有上述情况的发生。最近,有研究人员确定了促使患者做出AR治疗决定的关键因素。为了达到上述目的,研究人员利用一个社交网络理论构架来描绘出患者的AR网络,并且在该网络中鉴定影响